Logo Image
News|Articles|March 10, 2026

Novo Nordisk and Hims & Hers Partner to Expand Semaglutide Access

Listen
0:00 / 0:00

Key Takeaways

  • Agreement enables Hims & Hers users to access branded Ozempic 0.5–2 mg and Wegovy injectable 0.25–2.4 mg plus oral strengths 1.5–25 mg.
  • Hims & Hers will cease marketing compounded GLP-1 products and offer a clinician-guided transition pathway to FDA-approved semaglutide when clinically appropriate.
SHOW MORE

Hims & Hers will offer branded semaglutide instead of compounded GLP-1 drugs.

Novo Nordisk announced a strategic agreement with the telehealth provider Hims & Hers to expand US patient access to its FDA-approved semaglutide products.1 The collaboration signifies a major pivot in the GLP-1 access landscape, as Hims & Hers transitions its weight-loss business model away from compounded offerings toward branded medications.1

Under the terms of the agreement, which takes effect later this month, Hims & Hers will offer access to Ozempic® (semaglutide) injection in 0.5 mg, 1 mg, and 2 mg doses.1 Furthermore, the platform will provide access to Wegovy® (semaglutide) in both injectable and oral tablet forms.1 The oral formulation, recently launched as a highly anticipated weight-loss treatment, will be available in 1.5 mg, 4 mg, 9 mg, and 25 mg strengths, while the injectable Wegovy will be offered in doses ranging from 0.25 mg to 2.4 mg.1

According to Novo Nordisk, these medications will be provided to US consumers “at the same affordable self-pay prices as other telehealth platforms”.1 This price parity is intended to ensure consistent drug access across digital care channels, meeting patients wherever they choose to receive healthcare services, the company said.1

Why Is Hims & Hers Shifting From Compounded GLP-1s to FDA-Approved Medications?

A central element of this agreement is the cessation of compounded GLP-1 promotion by Hims & Hers. According to Novo Nordisk, the telehealth company will “no longer advertise compounded GLP-1 offerings on its platform or in its marketing.”1 Furthermore, for the thousands of patients currently utilizing compounded versions of these drugs, the agreement provides a pathway for clinical transition.2 As stated in the announcement, “existing patients will have the opportunity to transition to FDA-approved alternatives when clinically appropriate in consultation with a healthcare professional.”1

This shift follows significant regulatory pressure and legal tension. In February 2026, Novo Nordisk initiated litigation against Hims & Hers for what it described as "mass illegal compounding," after the telehealth firm announced a $49 off-brand version of the Wegovy pill—roughly $100 less than the branded version's price on Novo’s direct-to-consumer platform.2 Concurrently, the Food and Drug Administration (FDA) threatened to restrict access to the bulk ingredients required for compounding these medications, noting that GLP-1 drugs were no longer in a shortage.3

What Are the Clinical Significance and Trial Data?

Novo Nordisk's leadership emphasized that the agreement prioritizes patient safety by focusing on medicines evaluated for efficacy.

“This agreement with Hims & Hers is a meaningful win for patients in the United States. By expanding access through leading telehealth providers and digital care platforms, we are helping to connect more people with our FDA-approved medicines, which have been evaluated for safety and efficacy,” said Mike Doustdar, President and CEO of Novo Nordisk.1

The clinical utility of these branded products is supported by robust trial data, particularly the OASIS 4 trial.1 In this study of 307 adults, the Wegovy pill demonstrated an average weight loss of about 17% (16.6%) when patients remained on treatment, compared to just 3% for the placebo group.1 Beyond weight loss, the therapeutic value of these molecules extends to cardiovascular health. Doustdar noted, “Wegovy is not simply an obesity therapy. It is a clinically proven treatment that helps adults with obesity lose weight while also reducing the risk of cardiovascular events in patients who also have heart disease.”1

What Are the Legal and Market Implications?

In light of the new partnership, Novo Nordisk is dismissing its patent infringement lawsuit against Hims & Hers, while reserving the right to refile in the future.1 This legal resolution sparked a significant market reaction, with shares of Hims & Hers Health Inc. surging more than 36% in morning trading following the announcement.3

While the agreement effectively ends the current dispute, Novo Nordisk remains protective of its intellectual property, which is patent-protected in the U.S. until 2032.2

References

Related Content